Evidence map›Paper›PMID 40275334›Full record

ReviewBMC medicine2025

Artificial intelligence tool development: what clinicians need to know?

Boon-How Chew, Kee Yuan Ngiam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Consensus statement on the application of artificial intelligence in osteoporosis screening and management: perspectives from the Asia-Pacific region.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Boon-How ChewDepartment of Biomedical Informatics, Yong Loo Lin School of Medicine, National University of Singapore C/O NUHS Tower Block, Level 8, 1E Kent Ridge Road, Singapore, 119228, Singapore. chewboonhow@upm.edu.my.
Kee Yuan NgiamDepartment of Biomedical Informatics, Yong Loo Lin School of Medicine, National University of Singapore C/O NUHS Tower Block, Level 8, 1E Kent Ridge Road, Singapore, 119228, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digital medicine and smart healthcare will not be realised without the cognizant participation of clinicians. Artificial intelligence (AI) today primarily involves computers or machines designed to simulate aspects of human intelligence using mathematically designed neural networks, although early AI systems relied on a variety of non-neural network techniques. With the increased complexity of the neural layers, deep machine learning (ML) can self-learn and augment many human tasks that require decision-making on the basis of multiple sources of data. Clinicians are important stakeholders in the use of AI and ML tools. The review questions are as follows: What is the typical process of AI tool development in the full cycle? What are the important concepts and technical aspects of each step? This review synthesises a targeted literature review and reports and summarises online structured materials to present a succinct explanation of the whole development process of AI tools. The development of AI tools in healthcare involves a series of cyclical processes: (1) identifying clinical problems suitable for AI solutions, (2) forming project teams or collaborating with experts, (3) organising and curating relevant data, (4) establishing robust physical and virtual infrastructure, and computer systems' architecture that support subsequent stages, (5) exploring AI neural networks on open access platforms before making a new decision, (6) validating AI/ML models, (7) registration, (8) clinical deployment and continuous performance monitoring and (9) improving the AI ecosystem ensures its adaptability to evolving clinical needs. A sound understanding of this would help clinicians appreciate the development of AI tools and engage in codesigning, evaluating and monitoring the tools. This would facilitate broader use and closer regulation of AI/ML tools in healthcare settings.

Indexed as

Artificial IntelligenceHumansNeural Networks, ComputerArtificial intelligenceDeploymentDevelopmentInfrastructureIntegration clinical workflowMachine learning

Identifiers

PMID40275334
PMCPMC12023651

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.